

## NOTICE

**(Regarding the record date for entitlement to 2025 dividend payment in shares)**

**To: Vietnam Securities Depository and Clearing Corporation (VSDC)**

Name of the securities registration organization: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Trading name: AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Head office: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

Telephone: (+84) 296 3856961 – 3856964

Fax: (+84) 296 3857301

**We hereby notify the Vietnam Securities Depository and Clearing Corporation (VSDC) of the record date for determining the list of securities holders for the following securities:**

Name of share: Shares of Agimexpharm Pharmaceutical Joint Stock Company

Stock code: AGP

Share type: Common shares

Par value: VND 10,000/share

Trading market: UPCOM

Record date: May 29, 2026

**1. Purpose:** 2025 dividend payment in shares

**2. Detailed content:** Dividend payment in shares

- Subscription ratio: 25:03 (For every 1 share owned, a shareholder will receive 1 right to subscribe for additional shares. Every 25 rights will entitle the shareholder to 3 additional new shares).

- Plan to handle the fractional shares: The number of additional shares issued to each shareholder will be rounded down to the nearest whole number, and any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 122 shares as of the record date. With a subscription ratio of 25:03, Shareholder A is entitled to receive  $(122 * 3 / 25) = 14.64$  new shares. Following this calculation method, Shareholder A will receive 14 additional shares, and the fractional portion of 0.64 shares will be canceled.*

The difference between the total projected amount for issuing shares to pay dividends (calculated at a par value of VND 10,000 per share) and the total value of shares actually distributed to existing shareholders (calculated at a par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

- Place of implementation:

+ For deposited securities: Shareholders shall carry out procedures to receive share dividends at the depository members where their securities accounts are opened.


+ For undeposited securities: Shareholders shall carry out procedures to receive share dividends at the Accounting Department of Agimexpharm Pharmaceutical Joint Stock Company (*Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam*) and present their Citizen Identification Card/ID.

**We respectfully request VSDC to prepare and provide us with the list of securities holders as of the above-mentioned record date via the VSDC electronic portal system.**

***Recipients:***

- As above;
- Stock Exchange...;
- Archived: BOD Secretariat.

**LEGAL REPRESENTATIVE  
GENERAL DIRECTOR**



**PHARM. NGUYEN VAN KHA**

**\* Attachments:**

- Copy of Official Letter No. 3336/UBCK-QLCB dated April 23, 2026 issued by the State Securities Commission regarding receipt of complete dossier for share issuance for dividend payment of AGP;
- Copy of the Resolution of the 2026 Annual General Meeting of Shareholders No. 01/NQ-AGP.DHDCD dated March 27, 2026;
- Copy of Proposal No. 02/TT-AGP.DHDCD dated March 3, 2026 on profit distribution and dividend payment;
- Copy of Proposal No. 05/TT-AGP.DHDCD dated March 3, 2026 on the plan for share issuance for 2025 dividend payment.

**MINISTRY OF FINANCE  
STATE SECURITIES COMMISSION  
OF VIETNAM**

**THE SOCIALIST REPUBLIC OF VIETNAM**  
**Independence – Freedom – Happiness**

*Hanoi, April 23, 2026*

No.: 3336/UBCK-QLCB

Re: Dossier for reporting the issuance of  
shares for dividend payment of AGP



To: Agimexpharm Pharmaceutical Joint Stock Company

The State Securities Commission of Vietnam (SSC) has received the dossier for reporting the issuance of shares for dividend payment in accordance with Issuance Report No. 04/BC-AGP dated April 6, 2026 of Agimexpharm Pharmaceutical Joint Stock Company (the “Company”) (Stock code: AGP, registered for trading on UPCoM). The SSC provides the following opinions:

1. Agimexpharm Pharmaceutical Joint Stock Company and the organizations and individuals related to the reporting dossier shall comply with the provisions of Article 11a of the Law on Securities No. 54/2019/QH14, as amended and supplemented by Law No. 56/2024/QH15 (hereinafter referred to as the “Law on Securities”), and Clause 1, Article 6 of Decree No. 155/2020/ND-CP dated December 31, 2020, as amended and supplemented under Point b, Clause 3, Article 1 of Decree No. 245/2025/ND-CP dated September 11, 2025.

2. The SSC receives and processes the reporting dossier in accordance with Clause 2, Article 11a of the Law on Securities and Point d, Clause 1, Article 6 of Decree No. 155/2020/ND-CP dated December 31, 2020, as amended and supplemented under Point b, Clause 3, Article 1 of Decree No. 245/2025/ND-CP dated September 11, 2025.

3. The SSC has published on its official website the receipt of the complete reporting dossier of the Company. The issuance plan shall be implemented in accordance with the Resolution of the 2026 Annual General Meeting of Shareholders No. 01/NQ-AGP.DHDCD dated March 27, 2026, the Resolution of the Board of Directors No. 06/NQ-AGP.HDQT dated April 6, 2026, and the applicable laws and regulations.

4. The SSC requests the Company to disclose information and carry out the share issuance in accordance with Article 69 of Decree No. 155/2020/ND-CP.

The SSC hereby notifies the Company for information and implementation.

***Recipients:***

- As above;
- Chairman of the SSC (for reporting);
- Vice Chairman H.V. Thu (for reporting);
- Supervisory Board of Public Companies;
- Hanoi Stock Exchange (HNX); Vietnam Securities Depository and Clearing Corporation (VSDC);
- Archived: Administration, Public Company Management Department (08b).

**FOR THE CHAIRMAN  
HEAD OF THE PUBLIC OFFERING  
MANAGEMENT DEPARTMENT**

**Khuong Tien Hung**

## **RESOLUTION**

### **The 2026 Annual General Meeting of Shareholders**

#### **GENERAL MEETING OF SHAREHOLDERS**

#### **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, and its amending and supplementing documents;

Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company;

Pursuant to the voting results on matters approved at the 2026 Annual General Meeting of Shareholders of Agimexpharm Pharmaceutical Joint Stock Company, held at Hoa Binh 1 Restaurant on March 27, 2026.

#### **RESOLVED:**

**Article 1.** Approval of Report and evaluation of the Board of Directors' performance in 2025; objectives and plan for 2026; *Voting rate: 100%*.

**Article 2.** Approval of Audited Financial Statements for 2025; *Voting rate: 100%*.

**Article 3.** Approval of Report on use of funds raised from the share issuance to increase charter capital; *Voting rate: 100%*.

**Article 4.** Approval of Report on business performance in 2025 and the business plan for 2026 of the Board of Management; *Voting rate: 100%*.

**Article 5.** Approval of Report of the Board of Supervisors for 2025; *Voting rate: 100%*.

**Article 6.** Approval of the proposals presented by the Board of Directors and the Board of Supervisors:

- 1) Proposal on the selection of the auditing firm for the 2026 financial statements; *Voting rate: 100%*.
- 2) Proposal on profit distribution and dividend payment for 2025; *Voting rate: 100%*.
- 3) Proposal on remuneration and bonuses of the Board of Directors and the Board of Supervisors; *Voting rate: 100%*.
- 4) Proposal on addition of business lines and update of business names and codes; *Voting rate: 100%*.
- 5) Proposal on the share issuance plan to pay 2025 dividends; *Voting rate: 100%*.
- 6) Proposal on the share issuance plan under the Employee Stock Ownership Plan (ESOP); *Voting rate: 100%*.
- 7) Proposal on amendments and supplements to the Company's Charter; *Voting rate: 100%*.
- 8) Proposal on amendments and supplements to the Internal Regulations on Corporate Governance; *Voting rate: 100%*.
- 9) Proposal on amendments and supplements to the Operating Regulations of the Board of Directors; *Voting rate: 100%*.



**PROPOSAL**  
**ON PROFIT DISTRIBUTION AND DIVIDEND PAYMENT FOR 2025**  
(For the fiscal year ending 31 December, 2025)

**To: The 2026 Annual General Meeting of Shareholders**

Based on the actual situation and the Company's 2025 business performance as reflected in the audited 2025 Financial Statements, the Board of Directors respectfully submits to the 2026 Annual General Meeting of Shareholders for consideration and approval:

1. Adjustment of the 2025 Revenue and Profit before tax Plan (*pursuant to the Board of Directors' Resolution dated September 10, 2025*)

Items (Unit: VND billion)	Before adjustment	After adjustment
Revenue	868	818
Profit before tax	68	63.9

2. Profit distribution and Dividend payment for 2025:

Unit: VND (Vietnamese Dong)

Items	Percentage	Amount	Notes
Profit before tax		65,903,259,000	
Corporate income tax		13,861,821,387	
<b>Retained earnings</b>	<b>100%</b>	<b>52,041,437,613</b>	
1/ Appropriation to Bonus Fund for the Board of Directors and the Board of Supervisors	1.46%	759,195,540	
2/ Appropriation to the Reward and Welfare Fund	2.00%	1,040,828,752	
3/ Dividend payment: In form of shares ( <i>Details in the Proposal on Plan for issuing shares to pay dividends</i> )	70.58%	36,729,060,000	12%/Charter capital
4/ Remaining profit appropriated to Development and Investment Fund	25.96%	13,512,353,321	

**Notes:**

1/ Appropriation to the 2025 Bonus Fund for the Board of Directors and the Board of Supervisors as follows:

Total bonus fund for the Board of Directors: VND 759,195,540


Bonus for meeting the profit before tax plan (1% of profit before tax): VND 659,032,590

Bonus for exceeding the profit before tax plan (5% of excess profit): VND 100,162,950

2/ Development and Investment Fund, Reward and Welfare Fund: Used for expanding business operations, purchasing fixed assets (land, machinery, equipment, transportation, vehicles), scientific research, product development research, training, bonus share issuance, offsetting tax settlement differences, and losses in assets and debts. The Board of Directors authorizes the Board of Management to review the use of this fund within the limits as prescribed by law or the company's charter.

Sincerely.

ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRWOMAN



PHARM. PHAM THI BICH THUY

## **PROPOSAL**

### **On the share issuance plan to pay 2025 dividends**

**To: The General Meeting of Shareholders of Agimexpharm Pharmaceutical JSC**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 dated June 17, 2020, and its amending and supplementing documents;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, and its amending and supplementing documents;
- Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020 detailing a number of articles of the Law on Securities, as amended and supplemented by Decree No. 245/2025/ND-CP dated September 11, 2025;
- Pursuant to the Charter of Agimexpharm Pharmaceutical Joint Stock Company (“the Company”).

The Board of Directors (“BOD”) of Agimexpharm Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders (“GMS”) for consideration and approval the share issuance plan to pay 2025 dividends as follows:

1. **Name of share:** Shares of Agimexpharm Pharmaceutical Joint Stock Company
2. **Share type:** Common shares
3. **Par value:** VND 10,000/share
4. **Current charter capital:** VND 306,075,580,000
5. **Total number of issued shares:** 30,607,558 shares  
Of which: - Total number of outstanding shares: 30,607,558 shares  
- Total number of treasury shares: 0 shares
6. **Estimated number of shares to be issued:** 3,672,906 shares
7. **Total value of issuance at par value:** 36.729.060.000 đồng
8. **Eligible subscriber:** Existing shareholders whose names appear on the final shareholder list as of the record date. The record date for the shareholder list will be determined by the BOD, as authorized by the GMS.
9. **Issuance ratio** (estimated number of shares to be issued/number of outstanding shares): 12%
10. **Subscription ratio:** 25:03. For every 1 share owned, a shareholder will receive 1 right to subscribe for additional shares. Every 25 rights will entitle the shareholder to 3 additional new shares.
11. **Source of capital:** Retained earnings after tax as of December 31, 2025, based on the audited financial statements for the year 2025 of Agimexpharm Pharmaceutical Joint Stock Company.
12. **Issuance method:** The shares issued to existing shareholders will be distributed through the exercise of subscription rights.
13. **Plan to handle the fractional shares:** The number of additional shares issued to each shareholder will be rounded down to the nearest whole number, and any fractional shares (if any) will be canceled.

*For example: Shareholder A owns 122 shares as of the record date. With a subscription ratio of 25:03, Shareholder A is entitled to receive  $(122 * 3 / 25) = 14.64$  new shares. Following this calculation method, Shareholder A will receive 14 additional shares, and the fractional portion of 0.64 shares will be canceled.*

The difference between the total projected amount for issuing shares to pay dividends (calculated at a par value of VND 10,000 per share) and the total value of shares actually distributed to existing shareholders (calculated at a par value of VND 10,000 per share) will be allocated to the Company's Development Investment Fund.

**14. Expected time of issuance:** After the State Securities Commission (SSC) acknowledges receipt of the complete issuance report from the Company, the issuance is expected to take place in the second to fourth quarter of 2026. The GMS authorizes the BOD to determine the appropriate issuance time to ensure shareholders' interests and compliance with legal regulations.

**15. Additional securities registration and additional trading registration:** The GMS approves and authorizes the BOD to carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch and additional trading registration with the Hanoi Stock Exchange.

**16. Approval of charter capital increase:** Approval of amendments to the Company's Charter (Charter Capital section) and adjustment of the Enterprise Registration Certificate at the competent authority after the State Securities Commission of Vietnam confirms in writing the receipt of the issuance result report.

**17. Authorization to the BOD:**

The GMS authorizes the Company's BOD to carry out the following tasks related to the issuance:

- Make, amend, supplement, and finalize the content of the above-mentioned share issuance plan, and adjust the issuance plan along with other related documents as necessary, based on the actual situation of the Company, or as required by the SSC and other competent authorities, or to ensure compliance with relevant legal regulations (if any);
- Select the shareholder record date to implement the aforementioned share issuance plan;
- Make amendments and supplements to the relevant provisions in the Company's Charter to reflect the increased charter capital after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for additional securities registration with the Viet Nam Securities Depository and Clearing Corporation – Ho Chi Minh City Branch, and additional trading registration with the Hanoi Stock Exchange for the number of additional shares issued, based on the actual results of the issuance, after the SSC provides written notification of the receipt of the issuance result report;
- Carry out the procedures for amending the Company's business registration to reflect the change in charter capital based on the actual results of the issuance with competent authorities after the SSC provides written notification of the receipt of the issuance result report;
- Depending on specific circumstances, the BOD may authorize the General Director to carry out one or several specific tasks mentioned above;
- Make decisions on any other issues arising related to the issuance of shares for dividend payment.


**Respectfully submitted to the GMS for consideration and approval.**

**Sincerely thank you./.**

**Recipients:**

- Shareholders of the Company;
- Board of Directors;
- Archived: BOD Secretariat.

**ON BEHALF OF THE BOARD OF DIRECTORS  
CHAIRWOMAN**



**PHAR. PHAM THI BICH THUY**